---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008992"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T22:01:41.489421+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# AN2 Therapeutics reports Q1 2022 results, cash $118.4M; progresses epetraborole clinical program

## Summary
- Cash and investments total $118.4M as of March 31, 2022; expects operating runway through mid-2024.
- Upsized IPO raised $79.4M; full exercise of underwriter option added $10.4M in April.
- Phase 2/3 trial enrollment for treatment-refractory MAC lung disease expected to begin H1 2022.
- FDA cleared IND, granted Fast Track, QIDP, and orphan drug designation for epetraborole.
- Appointed Dr. Mel Spigelman and Maggie FitzPatrick to Board of Directors.

## SEC filing metadata
- accession: 0000950170-22-008992
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/0000950170-22-008992-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017022008992/antx-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008992
- JSON: https://secwatch.observer/filing/0000950170-22-008992.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008992.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.